Effect of Renal Sympathetic Denervation on Ventricular Electrical Activity in Myocardial Infarction

Xiaowei Qiu1, Zhengyu Feng1, Caixia Lin1

  • 1Department of Cardiology, Shanghai Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine.

Insights

Sympathetic renal denervation effectively reduces early recurrence of ventricular fibrillation after myocardial infarction (MI) and defibrillation. This therapy improves electrocardiogram (ECG) stability and reduces myocardial damage by lowering sympathetic nerve activity.

Area of Science:

  • Cardiology
  • Nephrology
  • Electrophysiology

Background:

  • Myocardial infarction (MI) frequently leads to ventricular fibrillation (VF), a serious cardiovascular condition.
  • Early recurrence of VF after defibrillation in post-MI patients is a significant clinical challenge.
  • Understanding the electrophysiological indicators and therapeutic interventions for early VF recurrence is crucial.

Purpose of the Study:

  • To investigate the relationship between electrophysiological indicators of early VF recurrence post-defibrillation in MI patients.
  • To evaluate the therapeutic benefits and underlying mechanisms of sympathetic renal denervation in this context.
  • To explore the impact of sympathetic renal denervation on myocardial damage and sympathetic nerve activity.

Main Methods:

  • Utilized animal models to study post-MI VF and defibrillation.
  • Administered sympathetic renal denervation to a subset of rats and compared outcomes to a control group.
  • Conducted electrocardiogram (ECG) monitoring, myocardial histology, and neurotransmitter assays.

Main Results:

  • Early VF recurrence post-defibrillation was associated with increased ST segment elevation and T wave alterations.
  • Sympathetic renal denervation significantly decreased early VF recurrence, leading to more stable ECG readings.
  • Histological analysis revealed reduced myocardial cellular damage and fibrosis in the intervention group.
  • Neurotransmitter assays indicated a significant reduction in sympathetic nerve activity following renal denervation.

Conclusions:

  • Sympathetic renal denervation demonstrates significant therapeutic benefits in reducing early VF recurrence after MI and defibrillation.
  • The intervention improves ECG parameters and mitigates myocardial damage, likely through decreased sympathetic nerve activity.
  • Sympathetic renal denervation represents a promising therapeutic strategy for managing post-MI ventricular arrhythmias.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336